BDSI inks $90M deal for pain patch

Sweden's Meda has agreed to pay BioDelivery Sciences $30 million upfront and more than $60 million in milestones in exchange for a licensing deal covering the North American rights to BEMA Fentanyl, a new pain patch for cancer patients. BioDelivery Sciences also stands to gain $30 million on FDA approval and another $30 million in sales milestones.

"It is optimal timing for us to acquire BEMA Fentanyl rights so soon after the acquisition of our U.S. platform MedPointe," says Anders Lonner, CEO of Meda AB. "Our ambition with this unique product within the breakthrough cancer pain indication is to reach well over $200 million in yearly sales."

- here's the release
- and here's the report from the News Observer

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.